Increased glioblastoma risk in patients with myeloproliferative neoplasms and myelodysplastic syndromes
Targeted therapies significantly extend the survival of patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS). It lays a reliable foundation on the interactions between MPN + MDS and GBM for future research, and offers insights for building multidisciplinary team collaboration.
Targeted therapies significantly extend the survival of patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS). It lays a reliable foundation on the interactions between MPN + MDS and GBM for future research, and offers insights for building multidisciplinary team collaboration.
What the study was
- Study design
- Mendelian randomization study
- Population
- Patients
- Category
- Other
- Maturity
- Exploratory
- Journal
- Clinical and experimental medicine
Why it surfaced
Matched Hematologic malignancies, Aging longevity and population health; Mendelian randomization study; human study; score 8/10 (n=2 r=3 dq=2 pop=1)
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.